PFE May 2024 31.000 put
| Previous close | 2.2000 |
| Open | 2.4500 |
| Bid | 2.0500 |
| Ask | 2.4600 |
| Strike | 31.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.4000 - 2.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 416 |
ZacksPfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GlobeNewswireArvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant d
- Reuters
UPDATE 1-Pfizer offers up to $250 mln to settle Zantac cancer lawsuits, FT reports
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
